179 results about "Inositol phosphate" patented technology

The present invention relates to a method for treating cancer using p38/JTV-1 and a method for screening pharmaceutical composition for treating cancer. More particularly, this invention relates to the method for treating cancer, which comprises administering the effective amount of p38/JTV-1 protein or a nucleic acid encoding for said protein to the patient and the method for screening a pharmaceutical composition for treating cancer characterized by selecting a substance having an effect on the increase of the activity of the p38/JTV-1 protein and the intracellular level thereof.

The method according to the invention can be effectively used to treat cancer through the mechanism of suppressing the proliferation of cancer cells by binding to FBP (FUSE-binding protein) and thereby promoting the ubiquitination of FBP to downregulate c-myc gene, which is a proto-oncogene, and the mechanism of promoting the apoptosis of cells by binding to PDK-1 (phosphoinositide-dependent protein) and thereby inhibiting the phosphorylation of AKT (serine/threonine kinase). Also, p38/JTV-1 can be used as a target for screening of new anticancer agents, by virtue of such regulation mechanisms of p38/JTV-1.

The methods and compositions disclosed herein concern the synthesis of a novel class of “two-headed” phospholipid-phosphoinositide hybrids possessing a carbon backbone, such as 2,3-diacylthreitol, erythritol or a synthetic module. The second phospholipid head group allows introduction of a biochemical or chemical moiety in a position orthogonal in space to those occupied by the phosphoinositide head group and the two acyl chains. The diacyl moieties allow for the incorporation of Pea-PIP₂ into a lipid bilayer, while the Ptdlns(4,5)P₂ moiety in the aqueous layer is specifically recognized by lipid binding proteins. In alternative embodiments of the invention, reporters, for example biotin, fluorophores and/or spin labels, are attached to the free amino group of the head groups of such molecules to specifically target the reporters to the lipid-water interface.

The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX. The immunoconjugate may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8 or 10 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.

This invention is directed to an acidic beverage composition, comprising; (A) a hydrated protein material having a combination of an inositol-6-phosphate content, an inositol-5-phosphate content, an inositol-4-phosphate content and an inositol-3-phosphate content of less than 8.0 μmol/g, with (B) a hydrated protein stabilizing agent and (C) at least one acid comprising a fruit juice, a vegetable juice, citric acid, malic acid, tartaric acid, lactic acid, ascorbic acid, glucono delta lactone or phosphoric acid, wherein the acidic beverage composition has a pH of from 3.0 to 4.5.

The invention discloses a photoresist cleaning agent composition, which contains alcohol amine compound, water-soluble polar organic solvent and water, and also contains one or several selected from inositol phosphate ester and inositol phosphate salt. The cleaning agent composition can effectively remove photoresist on a semiconductor wafer, etched or ash incinerated photoresist residues or other residues, simultaneously has weak corrosion for metals such as aluminum, copper and the like and nonmetallic materials such as silicon oxide and the like, and has good application prospect in the microelectronic field such as cleaning of semiconductor wafers and the like.

The present invention relates to a composition for gelatin coating and a gelatin coating characterized by containing a gelatin (A) and an inositol phosphate (B) represented by a general formula: C₆H_12-n.(H₂PO₄)_n (in the formula, n represents an integer from 1 to 6), and a preparation using the same.

The invention discloses a water-soluble electric contact lubricating protective agent improving the pluggable resistance of an electronic element and a use method thereof. The water-soluble electric contact lubricating protective agent comprises the following components in parts by weight: 10-15 parts of fatty alcohol and inositol phosphate, 3-6 parts of natural phospholipid, 3-8 parts of corrosion inhibitor, 10-20 parts of composite surfactant system, 15-25 parts of chelating agent, and 10-20 parts of detergent. A protective agent is adopted to lubricate the electronic element, and the protective agent is firstly diluted by 10-100 times with pure water, and preferably 100/8-100/4. Soaking technology is adopted for lubrication, the temperature is 20-60 DEG C, the time is 30-90 seconds, the drying temperature of a workpiece subjected to lubrication is 80-150 DEG C, and the time is 30-120 seconds. After the electronic element is treated by the protective agent disclosed by the invention, through a pluggable force test, an abrasion test and a salt fog test, the results show that the friction of the electronic element is obviously reduced, the pluggable resistance is obviously enhanced, and the long-term reliability of products is obviously improved.

The invention relates to new triazines (G=Q=U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E¹ is CR⁴ or N; X¹ is CHR⁴, CH₂CH₂, NR⁴, NR4→0, or O; and the other substituents are as defined in the specification. The compounds inhibit phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), DNA-PK and ATM kinase, and may be used as therapeutic agents or diagnostic probes. The invention also relates to methods of using the compounds for treatment of associated pathological conditions.

The invention discloses a silver ion sterilizing dispersible tablet which comprises the following components by weight percent: 10-40% of main materials, 0.5-5% of bonding agent, 15-45% of filling agent, 10-40% of disintegrating agent, 0-35% of effervescing agent, 0.1-3% of flow aid and 0.5-5% of lubricating agent, wherein the main materials comprise one or combination of two of nanometer silver particles and complex silver ions, as well as gamma-aminobutyric acid, inositol hexaphosphate and glutathione. The silver ion sterilizing dispersible tablet enters into a single-cell bacterial body by utilizing the silver ions to interfere metabolism of the single-cell bacterial body and damage protein capsid and DNA (deoxyribonucleic acid) molecules of the single-cell bacterial body so as to kill the single-cell bacterial body. When the bacterial body is inactivated, the silver ions drift away for re-sterilizing, so that the anti-bacterial effect is lasting. Meanwhile, the sterilizing effect of the silver ions is not influenced by drug resistance, so that the killing effect of pathogenic bacteria with drug resistance is good and new drug resistance is not produced at the same time due to mechanism of action.

The present invention is directed to a nutritional formula for feeding human infants comprising isolated soy protein wherein the isolated soy protein has (a) a degree of hydrolysis of from about 0.5% up to about 30%; (b) a combination of an inositol-6-phosphate content, an inositol-5-phosphate content, an inositol-4-phosphate content and an inositol-3-phosphate content of less than about 8.0 μmol/g soy protein on a moisture free basis; and (c) a nitrite content of less than about 10 parts per million. Optionally, the isolated soy protein for the nutritional formula has a free amino acid content of up to about 25%. Further, the isolated soy protein for the nutritional formula optionally has a calcium content of from about 1.0% up to about 12%.

The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease.

The invention provides a preparation method of autologous natural killer cell proliferation and culture. The preparation method of the autologous natural killer cell proliferation and culture is characterized in that mononuclear cells of a cancer patient are amplified and activated to obtain natural killer cells after the mononuclear cells are transfected by 3- phosphoinositide-dependent protein kinase-1 and CD122 and under the effect of K562 cells which are expressed stably serve as trophoblast cells and interleukin 2, proliferation times of the natural killer cells are above 2500, phenotype of CD16+/CD56+ is above 90%, and in-vivo and in-vitro tests show that the natural killer cells have an anti-tumor and have quite high killer toxicity. The invention also provides a kit which is used for autologous natural killer cell proliferation and culture and is obtained by using the preparation method. The kit has an efficient anti-tumor function.

The present invention relates to methods of treating Alzheimer's Disease which utilize agents that increase neuronal phosphotidylinositol 4,5-biphosphate (PIP2), and to differentiated stem cell-based assay systems that may be used to identify agents that modulate phosphoinositide levels and thereby treat a variety of diseases. It is based, at least in part, on the discovery that edelfosine, an agent that increases PIP2 levels by inhibiting an enzyme that catalyzes PIP2 breakdown, decreases levels of neurotoxic A&bgr;42 peptide, particularly in cells expressing a mutant presenilin gene associated with Familial Alzheimer's Disease.

The invention provides an anti-cancer sustained-release agent co-carrying glucocorticoid and chemotherapeutic drugs and belongs to sustained-release injections. The anti-cancer sustained-release agent comprises sustained-release microspheres and a solvent, wherein, the sustained-release microspheres comprise anti-cancer active components and sustained-release auxiliary materials; and the solvent is a particular solvent containing a suspending agent. The glucocorticoid is selected from prednisolone, methylprednisolone, dexamethasone, betemethasone, triamcinolone acetonide or triamcinolone acetonide; the chemotherapeutic drugs are selected from phosphoinositide 3-kinase inhibitor, pyrimidine analogues and the like; the sustained-release auxiliary materials are biocompatible high-polymers, such as polylactic acid and the copolymers thereof, polyethylene glycol, carboxyl-terminated polylactic acid copolymers, polyfatty acid dimer-sebacic acid copolymers, poly(erucic acid dimer-sebacic acid), poly(fumaric-co-sebacic acid), polifeprosan and the like; and the suspending agent with the viscosity being 100cp to 3,000cp (at the temperature of 20 to 30 DEG C) is selected from sodium carboxymethyl cellulose and the like. The anti-cancer active components and the sustained-release microspheres can further be prepared into sustained-release implants which can effectively inhibit the growth of tumors, alleviate edema and improve the curative effects of radiotherapy and chemotherapy by intra-tumor or peri-tumor injection or placement.

Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.

The invention relates to compound orthophthalaldehyde disinfectant, and a preparation method and application thereof. The compound orthophthalaldehyde disinfectant is prepared from orthophthalaldehyde (1), tetrakis hydroxymethyl phosphonium sulfate (2), inositol phosphate (3), a penetrating agent (4), ampholyticsurfactant (5) and deionized water (6). The compound orthophthalaldehyde disinfectant is characterized by that each 1000ml compound orthophthalaldehyde disinfectant comprising 1.0 to 102.4g of the orthophthalaldehyde and 1.3 to 133.3g of inositol phosphate. The compound orthophthalaldehyde disinfectant can kill enteropathogenic bacteria, pyogenic cocci, hepatitis virus, avian influenza virus, various epidemic diseases, bacterial spore and the like, and is applicable to performing sterilization on articles in farms, environments, air, ground, water, epidemic focus, health and epidemic prevention and the like.

The invention belongs to the technical field of assisted reproduction, and relates to an oocyte activating solution and application thereof. The oocyte activating solution comprises 1.1 to 1.8 mg/L ofionomycin, 6 to 12 mg/L of calcium ion carrier A23187, 63 to 94 mug/L of puromycin, 19 to 43 mg/L of 6DMAP, 3.4 to 6.6 mg/L of actinone CHX, 28 to 53 mug/L of phorbol PMA, 7.8 to 12.7 mug/L of inositol triphosphate, 1.5 to 2.4 g/L of SrCl2, 16 to 25 mg/L of heparin, and basic culture medium. The oocyte activating solution can effectively activate oocytes, and is suitable for activating the oocytes after ICSI in an in-vitro fertilization assisted reproduction technology.

Disclosed is a cement material comprising a powder of a calcium salt having inositol phosphate and/or a salt thereof adsorbed on its surface, wherein the powder has a specific surface area of 60 to 120 m²/g. Also disclosed is a process for producing a cement material, comprising the steps of: mixing a solution containing a calcium ion and adjusted to an alkaline pH value with a solution containing a phosphate ion to produce a precipitate; aging the system containing the precipitate to produce a powder of the calcium salt: collecting and drying the powder of the calcium salt; and immersing the dried powder of the calcium salt in a solution of inositol phosphate and/or a salt thereof to cause the adsorption of the inositol phosphate and/or the salt thereof onto the surface of the powder of the calcium salt.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and/or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders/other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.